Company
Headquarters: Brisbane, QLD, Australia
Employees: 500
CEO: Dr. Anthony Keating
A$176.2 Million
AUD as of Sept. 1, 2022
US$120.1 Million
Company | Market Cap (USD) |
---|---|
GE HealthCare | $35.26 B |
Veeva Systems Inc. | $29.31 B |
Change Healthcare Inc. | $9.03 B |
Pro Medicus Limited | $8.96 B |
Signify Health, Inc. | $8.38 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a smartphone application that allows consumers to self-assess the risk of sleep apnoea. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. ResApp Health Limited has a joint development and pilot agreement with Medgate AG to integrate and test smartphone-based acute respiratory diagnostic test. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was incorporated in 2000 and is headquartered in Brisbane, Australia.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
ResApp Health Limited has the following listings and related stock indices.
Stock: ASX: RAP wb_incandescent